Log in
(Ad)
A devastating technical glitch could crush the next generation of wireless technology before it even launches. With trillions of dollars and millions of jobs at stake, one company with the "5G fix" could put as much as $234,770 in your pocket this year. But Wall Street vultures are circling... you'll need to move quickly or risk missing this $5 bargain.

CVE:NTB - Neptune Technologies & Bioressources Stock Price, Forecast & News

Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume31,049 shs
Average Volume315,395 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Neptune Technologies & Bioressources Inc. (Neptune) is a biotechnology company. The Company is engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids (PUFAs). The Company operates in three segments: Neptune, Acasti Pharma Inc. and Acasti Pharma Inc. Its Neptune produces and commercializes nutraceutical products. Its Acasti Pharma Inc. develops and commercializes pharmaceutical applications for cardiovascular diseases. Its NeuroBioPharm Inc. develops and commercializes pharmaceutical applications for neurological diseases. It produces omega-3 PUFAs through its patented process of extracting oils from Antartic krill, which omega-3 PUFAs are then principally sold as bulk oil to Neptune's distributors who commercialize them under their private label primarily in the United States, European and Australian nutraceutical markets. The Company's products include Neptune Krill Oil (NKO) and ECOKRILL Oil (EKO).

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
CUSIPN/A
CIKN/A
Phone+1-450-6872262

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive NTB News and Ratings via Email

Sign-up to receive the latest news and ratings for NTB and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

What if you could buy one tiny stock today for $10 - at the center of a growing tech industry - that experts believe will explode a massive 77,400%?

Wall Street legend Paul Mampilly recently identified this as the stock of the century.

Buying up a handful of shares of this small company now could change your life and even make you millions.

Neptune Technologies & Bioressources (CVE:NTB) Frequently Asked Questions

What is Neptune Technologies & Bioressources' stock symbol?

Neptune Technologies & Bioressources trades on the Canadian Venture Exchange (CVE) under the ticker symbol "NTB."

How were Neptune Technologies & Bioressources' earnings last quarter?

Neptune Technologies & Bioressources Inc (CVE:NTB) announced its quarterly earnings data on Tuesday, July, 15th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.08) by $0.02. The biotechnology company had revenue of $3.69 million for the quarter, compared to analyst estimates of $7.31 million. View Neptune Technologies & Bioressources' Earnings History.

Has Neptune Technologies & Bioressources been receiving favorable news coverage?

News articles about NTB stock have been trending negative this week, InfoTrie reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Neptune Technologies & Bioressources earned a coverage optimism score of -2.4 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Neptune Technologies & Bioressources.

What other stocks do shareholders of Neptune Technologies & Bioressources own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neptune Technologies & Bioressources investors own include ArQule (ARQL), Obseva (OBSV), Omnicell (OMCL), ZIOPHARM Oncology (ZIOP), Canopy Growth (CGC), Magellan Midstream Partners (MMP), Home Capital Group (HCG), Storm Resources (SRX), Evotec (EVT) and Strategic Oil & Gas (SOG).

Who are Neptune Technologies & Bioressources' key executives?

Neptune Technologies & Bioressources' management team includes the folowing people:
  • John Moretz, Chairman of the Board
  • James Stuart Hamilton, President, Chief Executive Officer, Director
  • Mario Paradis, Chief Financial Officer
  • Michel Timperio, Senior Vice President of Sales - Global Sales
  • Pierre Lemieux Ph.D., Chief Operating Officer of Acasti
  • Jean-Daniel Belanger, Corporate Secretary and Director - Corporate Affairs
  • Harlan W. Waksal M.D., Director (Age 61)
  • Valier Boivin, Independent Director
  • Ronald Denis, Independent Director
  • Adrian Taylor Montgomery, Independent Director

How do I buy shares of Neptune Technologies & Bioressources?

Shares of NTB and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Neptune Technologies & Bioressources' official website?

The official website for Neptune Technologies & Bioressources is http://neptunekrilloil.com/.

How can I contact Neptune Technologies & Bioressources?

Neptune Technologies & Bioressources' mailing address is 545 Prom du Centropolis Suite 100, LAVAL, QC H7T 0A3, Canada. The biotechnology company can be reached via phone at +1-450-6872262.


MarketBeat Community Rating for Neptune Technologies & Bioressources (CVE NTB)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  44 (Vote Outperform)
Underperform Votes:  43 (Vote Underperform)
Total Votes:  87
MarketBeat's community ratings are surveys of what our community members think about Neptune Technologies & Bioressources and other stocks. Vote "Outperform" if you believe NTB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel